CA2845810C - Anti-ox40 antibodies and methods of using the same - Google Patents

Anti-ox40 antibodies and methods of using the same Download PDF

Info

Publication number
CA2845810C
CA2845810C CA2845810A CA2845810A CA2845810C CA 2845810 C CA2845810 C CA 2845810C CA 2845810 A CA2845810 A CA 2845810A CA 2845810 A CA2845810 A CA 2845810A CA 2845810 C CA2845810 C CA 2845810C
Authority
CA
Canada
Prior art keywords
cells
antibody
antibodies
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2845810A
Other languages
English (en)
French (fr)
Other versions
CA2845810A1 (en
Inventor
Yong-Jun Liu
Kui Shin Voo
Laura Bover
Naoya Tsurushita
J. Yun Tso
Shankar Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/048752 external-priority patent/WO2012027328A2/en
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2845810A1 publication Critical patent/CA2845810A1/en
Application granted granted Critical
Publication of CA2845810C publication Critical patent/CA2845810C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2845810A 2011-08-23 2012-02-09 Anti-ox40 antibodies and methods of using the same Expired - Fee Related CA2845810C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/048752 2011-08-23
PCT/US2011/048752 WO2012027328A2 (en) 2010-08-23 2011-08-23 Anti-ox40 antibodies and methods of using the same
PCT/US2012/024570 WO2013028231A1 (en) 2011-08-23 2012-02-09 Anti-ox40 antibodies and methods of using the same

Publications (2)

Publication Number Publication Date
CA2845810A1 CA2845810A1 (en) 2013-02-28
CA2845810C true CA2845810C (en) 2017-03-28

Family

ID=47747183

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2845810A Expired - Fee Related CA2845810C (en) 2011-08-23 2012-02-09 Anti-ox40 antibodies and methods of using the same

Country Status (9)

Country Link
EP (1) EP2748199B1 (from)
JP (1) JP6038920B2 (from)
KR (1) KR101685262B1 (from)
CN (1) CN103946238B (from)
AU (2) AU2012299421B2 (from)
CA (1) CA2845810C (from)
RU (1) RU2562874C1 (from)
TN (1) TN2013000076A1 (from)
WO (1) WO2013028231A1 (from)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2013006771A0 (en) 2010-08-23 2013-03-31 Boards Of Regents The University Of Texas System Anti-OX40 antibodies and methods of using the same
DK2925350T3 (da) 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
DK2976361T3 (en) * 2013-03-18 2018-10-01 Biocerox Prod Bv HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
US9587032B2 (en) * 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
HRP20231437T1 (hr) 2013-08-08 2024-02-16 Cytune Pharma Il-15 i il-15ralpha sushi domena na temelju modulokina
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2690670C2 (ru) * 2014-03-12 2019-06-05 Ида Рисерч Энд Дивелопмент Ко., Лтд Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
EP3322443A1 (en) * 2015-07-13 2018-05-23 Yeda Research and Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
SMT201900702T1 (it) 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
CA2981183A1 (en) 2015-04-07 2016-10-13 Greg Lazar Antigen binding complex having agonistic activity and methods of use
EA201792451A1 (ru) * 2015-05-07 2018-05-31 Агенус Инк. Антитела к ox40 и способы их применения
EP3310810A1 (en) 2015-06-16 2018-04-25 Merck Patent GmbH Pd-l1 antagonist combination treatments
US20180222990A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
WO2017021911A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
MX2018003820A (es) 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
JP6771551B2 (ja) * 2015-10-15 2020-10-21 ディンフー バイオターゲット カンパニー リミテッド 抗ｏｘ４０抗体及びその応用
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
IL295649B2 (en) 2016-04-07 2025-12-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
BR112018072740A2 (pt) 2016-05-05 2019-02-19 Glaxosmithkline Intellectual Property (No. realçador de inibidores de homólogo 2 de zeste
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
EP3487503A1 (en) 2016-07-20 2019-05-29 GlaxoSmithKline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN109843324A (zh) 2016-10-06 2019-06-04 辉瑞公司 用于治疗癌症的avelumab用药方案
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
CA3045241A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
EP3548068A1 (en) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
US10556962B2 (en) * 2016-12-15 2020-02-11 Abbvie Biotherapeutics Inc. Anti-OX40 antibodies and their uses
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018150326A1 (en) 2017-02-15 2018-08-23 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN110573504A (zh) 2017-02-27 2019-12-13 葛兰素史克知识产权开发有限公司 作为激酶抑制剂的杂环酰胺
CN108623685B (zh) * 2017-03-25 2022-07-01 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
CA3066007A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2018225034A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
CN107266568A (zh) * 2017-07-07 2017-10-20 无锡傲锐东源生物科技有限公司 抗foxp3蛋白单克隆抗体及其用途
CN109232738B (zh) * 2017-07-11 2021-11-09 南京金斯瑞生物科技有限公司 一种抗人ox40单克隆抗体及其应用
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
KR20200074214A (ko) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
MX2020004571A (es) 2017-11-01 2020-08-24 Hoffmann La Roche Contorsbodies 2+1 biespecificos.
DK3710576T3 (da) 2017-11-17 2025-01-02 Iovance Biotherapeutics Inc Til-ekspansion fra finnålsaspirater og små biopsier
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
TW202003555A (zh) 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN120943884A (zh) 2018-03-27 2025-11-14 百时美施贵宝公司 使用紫外线信号实时监测滴度
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
MX2021004953A (es) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Seleccion de celulas t reactivas al tumor mejoradas.
CN113272421B (zh) 2018-11-05 2025-02-18 艾欧凡斯生物治疗公司 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
US12343380B2 (en) 2018-11-05 2025-07-01 Iovance Biotherapeutics, Inc. Expansion of TILs utilizing AKT pathways inhibitors
SG11202104663PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Treatment of nsclc patients refractory for anti-pd-1 antibody
EP3885365A1 (en) * 2018-11-20 2021-09-29 Shanghai Pharmaexplorer Co., Ltd. Ox40 antibody, preparation method thereof and use thereof
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US12195545B2 (en) 2018-12-25 2025-01-14 Hanx Biopharmaceutics, Inc Anti-OX40 monoclonal antibody and application thereof
BR112021014911A2 (pt) 2019-02-01 2021-11-23 Glaxosmithkline Ip Dev Ltd Belantamabe mafodotina em combinação com pembrolizumabe para tratamento de câncer
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
CN110003338B (zh) * 2019-04-16 2021-04-23 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
US20230295313A1 (en) 2019-06-26 2023-09-21 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021029368A1 (ja) 2019-08-09 2021-02-18 国立研究開発法人理化学研究所 人工アジュバントベクター細胞と免疫賦活化剤との併用
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
AU2020355614B2 (en) 2019-09-27 2024-12-05 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
US20220389381A1 (en) 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
AU2020391231A1 (en) 2019-11-27 2022-07-14 Turnstone Biologics Corp. Method of producing tumor-reactive T cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JOP20220151A1 (ar) 2019-12-17 2023-01-30 Amgen Inc ناهض مستقبل إنترلوكين -2 / tnf المزدوج للاستخدام في العلاج
JP7662644B2 (ja) 2019-12-18 2025-04-15 シーティーエックスティー・ピーティーワイ・リミテッド 化合物
BR112022014562A2 (pt) 2020-01-28 2022-09-13 Glaxosmithkline Ip Dev Ltd Tratamentos de combinação, usos e métodos dos mesmos
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
HRP20250628T1 (hr) 2020-12-28 2025-07-18 Bristol-Myers Squibb Company Mješavine antitijela i postupci njihove upotrebe
JP2024509529A (ja) 2021-03-02 2024-03-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｄｎｍｔ１阻害剤としての置換ピリジン
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240166747A1 (en) 2021-03-31 2024-05-23 Glazosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024525475A (ja) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションを促進するように操作された免疫細胞及びその使用
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004041A1 (en) * 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
ES2295639T3 (es) * 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US7786266B2 (en) * 2005-05-12 2010-08-31 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-DSC2 antibody
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
TW200732349A (en) * 2005-12-16 2007-09-01 Genentech Inc Anti-OX40L antibodies and methods using same
US20110008368A1 (en) * 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
AU2008219666A1 (en) * 2007-02-27 2008-09-04 Genentech, Inc. Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
DK2242771T3 (da) * 2007-12-14 2013-08-26 Pfizer Bindingsmolekyler til den humane ox40-receptor
SG2014014708A (en) * 2009-02-17 2014-05-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
AP2013006771A0 (en) * 2010-08-23 2013-03-31 Boards Of Regents The University Of Texas System Anti-OX40 antibodies and methods of using the same

Also Published As

Publication number Publication date
EP2748199B1 (en) 2019-08-28
JP6038920B2 (ja) 2016-12-07
CA2845810A1 (en) 2013-02-28
AU2016200435A1 (en) 2016-02-18
AU2012299421B2 (en) 2016-02-04
CN103946238A (zh) 2014-07-23
CN103946238B (zh) 2016-10-12
RU2562874C1 (ru) 2015-09-10
AU2016200435B2 (en) 2017-02-23
AU2012299421A1 (en) 2014-03-06
WO2013028231A1 (en) 2013-02-28
JP2014526898A (ja) 2014-10-09
TN2013000076A1 (en) 2014-06-25
KR101685262B1 (ko) 2016-12-21
KR20140090976A (ko) 2014-07-18
EP2748199A4 (en) 2015-06-17
EP2748199A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
US10851173B2 (en) Anti-OX40 antibodies and methods of using the same
CA2845810C (en) Anti-ox40 antibodies and methods of using the same
HK1184792A (en) Anti-ox40 antibodies and methods of using the same
HK1184792B (en) Anti-ox40 antibodies and methods of using the same
HK1213272B (en) Anti-ox40 antibodies and methods of using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150123

MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200210